Physician profile
Paul D Lyde
NPI 1336321207
$603.66
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $32.88 · 2021: $108 · 2022: $50.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $101.54 | 2019-2021 | |
| Lilly USA, LLC | $74.01 | 2019-2021 | |
| Zealand Pharma US, INC. | $72.82 | 2021-2022 | |
| Corcept Therapeutics | $53.72 | 2019 | |
| Valeritas, INC. | $45.50 | 2019 | |
| Merck Sharp & Dohme LLC | $41.29 | 2019 | |
| Novo Nordisk INC | $40.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.39 | 2019 | |
| Insulet Corporation | $32.78 | 2019 | |
| Becton, Dickinson and Company | $23.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.33 | 2019 | |
| Amarin Pharma, INC. | $18.41 | 2019 | |
| Mannkind Corporation | $14.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.08 | 2019 | |
| Abbott Laboratories | $12.00 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.